$MED
MEDIFAST INC Stock $med

$med Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024019046 Filed on April 29, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$168.6M	$174.7M
YoY Change	-43.09%	-49.93%
Cost Of Revenue	$45.12M	$47.45M
YoY Change	-47.21%	-53.75%
Gross Profit	$123.4M	$127.3M
YoY Change	-41.42%	-48.34%
Gross Profit Margin	73.23%	72.85%
Selling, General & Admin	$131.3M	$119.4M
YoY Change	-23.66%	-38.12%
% of Gross Profit	106.38%	93.76%
Research & Development	$1.100M	$1.000M
YoY Change	0.0%	0.0%
% of Gross Profit	0.89%	0.79%
Depreciation & Amortization	$3.067M	$3.261M
YoY Change	-8.94%	9.65%
% of Gross Profit	2.48%	2.56%
Operating Expenses	$131.3M	$119.4M
YoY Change	-23.66%	-38.12%
Operating Profit	-$7.876M	$7.940M
YoY Change	-120.35%	-85.16%
Interest Expense	$1.296M	$1.223M
YoY Change	180.52%	-775.69%
% of Operating Profit		15.4%
Other Income/Expense, Net	-$2.774M	$3.645M
YoY Change	-774.94%	-2102.75%
Pretax Income	-$10.65M	$11.59M
YoY Change	-127.23%	-78.28%
Income Tax	-$2.496M	$3.269M
% Of Pretax Income		28.22%
Net Earnings	-$8.154M	$8.316M
YoY Change	-126.93%	-79.19%
Net Earnings / Revenue	-4.84%	4.76%
Basic Earnings Per Share	-$0.75	$0.76
Diluted Earnings Per Share	-$0.75	$0.76
COMMON SHARES
Basic Shares Outstanding	10.94M shares	10.90M shares
Diluted Shares Outstanding	10.94M shares	10.96M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$163.5M	$156.4M
YoY Change	10.92%	26.41%
Cash & Equivalents	$108.0M	$97.47M
Short-Term Investments	$55.49M	$58.96M
Other Short-Term Assets	$12.48M	$11.41M
YoY Change	-0.3%	17.97%
Inventory	$39.60M	$46.27M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$224.3M	$219.6M
YoY Change	-1.97%	-4.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.92M	$50.99M
YoY Change	-26.63%	-8.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.77M	$13.65M
YoY Change	-17.51%	-0.44%
Total Long-Term Assets	$69.22M	$83.18M
YoY Change	-23.01%	-8.89%
TOTAL ASSETS
Total Short-Term Assets	$224.3M	$219.6M
Total Long-Term Assets	$69.22M	$83.18M
Total Assets	$293.5M	$302.8M
YoY Change	-7.9%	-5.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$69.15M	$71.23M
YoY Change	-34.26%	-37.13%
Accrued Expenses	$6.031M	$5.958M
YoY Change	11.58%	10.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$75.18M	$77.19M
YoY Change	-34.57%	-41.41%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.07M	$14.61M
YoY Change	-28.46%	-22.95%
Total Long-Term Liabilities	$13.07M	$14.61M
YoY Change	-28.46%	-22.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$75.18M	$77.19M
Total Long-Term Liabilities	$13.07M	$14.61M
Total Liabilities	$88.25M	$91.80M
YoY Change	-33.73%	-39.09%
SHAREHOLDERS EQUITY
Retained Earnings	$174.8M	$183.0M
YoY Change	6.69%	20.51%
Common Stock	$11.00K	$11.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$205.3M	$211.0M
YoY Change
Total Liabilities & Shareholders Equity	$293.5M	$302.8M
YoY Change	-7.9%	-5.86%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$8.154M	$8.316M
YoY Change	-126.93%	-79.19%
Depreciation, Depletion And Amortization	$3.067M	$3.261M
YoY Change	-8.94%	9.65%
Cash From Operating Activities	$13.07M	$7.282M
YoY Change	-69.71%	-88.63%
INVESTING ACTIVITIES
Capital Expenditures	$1.938M	$1.841M
YoY Change	11.12%	-12.96%
Acquisitions
YoY Change
Other Investing Activities	-$594.0K	-$934.0K
YoY Change
Cash From Investing Activities	-$2.532M	-$2.775M
YoY Change	45.18%	31.21%
FINANCING ACTIVITIES
Cash Dividend Paid		$710.0K
YoY Change		-96.29%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-20.00K	-$1.491M
YoY Change	-99.89%	-94.24%
NET CHANGE
Cash From Operating Activities	13.07M	$7.282M
Cash From Investing Activities	-2.532M	-$2.775M
Cash From Financing Activities	-20.00K	-$1.491M
Net Change In Cash	10.52M	$3.031M
YoY Change	-55.37%	-91.59%
FREE CASH FLOW
Cash From Operating Activities	$13.07M	$7.282M
Capital Expenditures	$1.938M	$1.841M
Free Cash Flow	$11.13M	$5.441M
YoY Change	-73.11%	-91.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	47447000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	102593000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	127292000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	246390000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	119352000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	192879000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	7940000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	53511000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1223000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-181000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2422000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3645000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-182000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11585000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	53329000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3269000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13361000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	8316000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	39968000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.76
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.68
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.76
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.67
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10909000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10864000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10958000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10899000	shares
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.65
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	8316000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	39968000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	15000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	9000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-241000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-226000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8090000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	39977000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97471000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94440000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	46273000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	54591000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	58957000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	55601000	usd
CY2024Q1	us-gaap	Prepaid Taxes PrepaidTaxes	5471000	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	8727000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11412000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10670000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	219584000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	224029000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50986000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51467000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14536000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15645000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13648000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14650000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	4005000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	4117000	usd
CY2024Q1	us-gaap	Assets Assets	302759000	usd
CY2023Q4	us-gaap	Assets Assets	309908000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	71229000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	86415000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5958000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5885000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	77187000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92300000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14611000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16127000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	91798000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	108427000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10937000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10937000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10896000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10896000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27963000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26573000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	22000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	248000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	182965000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	174649000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	210961000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	201481000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	302759000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	309908000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	8316000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	39968000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3261000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2974000	usd
CY2024Q1	med	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	1108000	usd
CY2023Q1	med	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	1369000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2171000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	606000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-13000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2024Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	9000	usd
CY2023Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2024Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	191000	usd
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	0	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	112000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	800000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	2437000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-8318000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-21960000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	742000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6563000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-24000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	887000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-15918000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-21897000	usd
CY2024Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-3256000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-12603000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7282000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	64059000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9169000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	8235000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1841000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2115000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2775000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2115000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	36000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	105000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	817000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	3236000	usd
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	710000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	19163000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3602000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1491000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-25896000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3031000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36057000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94440000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87691000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97471000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123748000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-100000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-46000	usd
CY2024Q1	us-gaap	Dividends Cash DividendsCash	697000	usd
CY2023Q1	us-gaap	Dividends Cash DividendsCash	18653000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	201481000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	8316000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2171000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	817000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-226000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	210961000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	155044000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	39968000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	606000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	105000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3236000	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	3602000	usd
CY2023Q1	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9000	usd
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	17994000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	170900000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div>
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	6343000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7944000	usd
CY2024Q1	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	1673000	usd
CY2023Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	1962000	usd
CY2024Q1	med	Inventory Non Food Finished Goods InventoryNonFoodFinishedGoods	2877000	usd
CY2023Q4	med	Inventory Non Food Finished Goods InventoryNonFoodFinishedGoods	3703000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	36769000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	43248000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1389000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2266000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	46273000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	54591000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	8316000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	39968000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10909000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10864000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	49000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	35000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10958000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10899000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.76
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.68
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.76
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.67
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	66.68
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	25000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.20
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	27.68
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	27.18
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	26.52
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	66.68
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	29000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.65
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	22000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	66.68
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	29000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	58.65
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M24D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	36000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	105000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	15000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	328000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	20569000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	466000	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2171000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	225000	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	606000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1500000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1563000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1804000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0230
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4749000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6462000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4783000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2553000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2618000	usd
CY2024Q1	med	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	240000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21405000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	836000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-33000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-48000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	55000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	296000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	22000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	248000	usd
CY2024Q1	med	Cash And Cash Equivalents Excluding Money Market Accounts Amortized Cost CashAndCashEquivalentsExcludingMoneyMarketAccountsAmortizedCost	92291000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	92291000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	153337000	usd
CY2024Q1	med	Investment Securities Unrealized Gains InvestmentSecuritiesUnrealizedGains	2755000	usd
CY2024Q1	med	Investment Securities Accrued Interest InvestmentSecuritiesAccruedInterest	336000	usd
CY2024Q1	med	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	156428000	usd
CY2023Q4	med	Cash And Cash Equivalents Excluding Money Market Accounts Amortized Cost CashAndCashEquivalentsExcludingMoneyMarketAccountsAmortizedCost	88778000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	88778000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	149162000	usd
CY2023Q4	med	Investment Securities Unrealized Gains InvestmentSecuritiesUnrealizedGains	569000	usd
CY2023Q4	med	Investment Securities Accrued Interest InvestmentSecuritiesAccruedInterest	310000	usd
CY2023Q4	med	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	150041000	usd
CY2024Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	9000	usd
CY2023Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	2437000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	2437000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	usd

Files In Submission

Name	View Source	Status
0001628280-24-019046-index-headers.html	Edgar Link	pending
0001628280-24-019046-index.html	Edgar Link	pending
0001628280-24-019046.txt	Edgar Link	pending
0001628280-24-019046-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
med-20240131xexx311.htm	Edgar Link	pending
med-20240131xexx312.htm	Edgar Link	pending
med-20240131xexx321.htm	Edgar Link	pending
med-20240331.htm	Edgar Link	pending
med-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
med-20240331_cal.xml	Edgar Link	unprocessable
med-20240331_def.xml	Edgar Link	unprocessable
med-20240331_lab.xml	Edgar Link	unprocessable
med-20240331_pre.xml	Edgar Link	unprocessable
med-20240331_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MED
MEDIFAST INC Stock $med

2024 Q2 Form 10-Q Financial Statement

#000162828024019046 Filed on April 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED MEDIFAST INC Stock $med

2024 Q2 Form 10-Q Financial Statement

#000162828024019046 Filed on April 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED
MEDIFAST INC Stock $med